Showing results (661-670 of 671) with videos related to
Sort By:
Pageof 68
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.Neuro-Oncology|March 22, 2025
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastomaPatrick Y Wen, Andrea Manzanera, Caroline Duault, et al.NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.Journal for Immunotherapy of Cancer|December 21, 2025
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales, et al.Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.Nature|November 6, 2007
Characterizing the cancer genome in lung adenocarcinomaBarbara A Weir, Michele S Woo, Gad Getz, et al.Cancer Discovery|May 19, 2018
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.Nature|October 25, 2008
Somatic mutations affect key pathways in lung adenocarcinomaLi Ding, Gad Getz, David A Wheeler, et al.Pageof 68